Last reviewed · How we verify
CMV CTL infusion
At a glance
| Generic name | CMV CTL infusion |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection (PHASE2)
- Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT (EARLY_PHASE1)
- Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone (PHASE3)
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. (PHASE1)
- Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) (PHASE1)
- Allogeneic Virus-specific T Cell Lines (VSTs) (PHASE1)
- CMV CTLs in Neonates With CMV Infection (PHASE2)
- Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CMV CTL infusion CI brief — competitive landscape report
- CMV CTL infusion updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI